KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies.

Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Filip Van den Bosch, Marina Magrey, Walter P Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Tom Vaux, Chetan Prajapati, Myriam Manente, Alexander Marten, Lianne S Gensler

Rheumatology (Oxford) 64(6) 3534-3546

PMID39798135
PMCIDPMC12107048
DOI10.1093/rheumatology/keaf009
发表日期2025-01-11
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:CONSORT/入组流程图。
摘要

摘要

OBJECTIVES: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, previously demonstrated efficacy and was well tolerated to 1 year in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). Here, we report bimekizumab safety and efficacy to 2 years. METHODS: Patients completing week 52 in the phase 3 studies BE MOBILE 1 (nr-axSpA; NCT03928704) and 2 (r-axSpA; NCT03928743) were eligible for an ongoing open-label extension (OLE; NCT04436640). All OLE patients received subcutaneous bimekizumab 160 mg every 4 weeks. Safety outcomes for patients who received ≥1 bimekizumab dose, and efficacy outcomes for all randomized patients, are reported to week 104. RESULTS: In the OLE (weeks 52 - 104), 70.8% (367/518) of patients reported ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs [exposure-adjusted incidence rate per 100 patient-years (EAIR/100PY)] were SARS-CoV-2 (COVID-19) infection (25.2), nasopharyngitis (11.0) and oral candidiasis (5.4). Fungal infection EAIR/100PY was 11.8 (majority Candida infections: 6.8; most mild/moderate, none serious/systemic). Inflammatory bowel disease and uveitis rates were low; no major adverse cardiovascular events or deaths occurred. TEAE incidence rate was generally similar across weeks 0 - 52 and 52 - 104.At week 104, >50% of randomized patients (N = 586) achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40); ∼60% achieved Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity (<2.1) and >30% achieved ASDAS inactive disease (<1.3). Bimekizumab demonstrated sustained suppression of MRI inflammation at week 104, with >57% of patients achieving MRI remission. CONCLUSIONS: The safety profile of bimekizumab remained consistent with prior reports, with no new safety signals identified. 1-year efficacy was sustained to 2 years across patients with nr-axSpA and r-axSpA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. ASAS and ASDAS outcomes to week 104. Randomized set; all patients treated with BKZ 160 mg Q4W from week 16. Data reported using NRI and OC from week 0 – 104, in addition to MI from week 52 – 104. The dashed vertical line between weeks 48 and 56 indicates entry into the combined open-label treatment period (BE MOVING) following week 52 of BE MOBILE 1 or BE MOBILE 2. ASAS: Assessment of SpondyloArthritis international Society; ASAS40: ASAS 40% response; ASDAS: Axial Spondyloarthritis Disease Activity Score; ASDAS ID: ASDAS inactive disease; ASDAS LDA: ASDAS low disease activity; BKZ: bimekizumab; CfB: change from baseline; MI: multiple imputation; NRI: non-responder imputation; OC: observed case; PBO: placebo; Q4W: every 4 weeks.
非 KM Figure
Figure 2Figure 2. ASDAS disease states to week 104 (MI). n =586. Includes all patients, including those originally randomized to placebo, and any with intercurrent events; all patients were treated with BKZ 160 mg Q4W from week 16. Values shown to the right of the bars at week 52 and week 104 represent the proportion of patients achieving ASDAS LDA (that is, ASDAS <1.3 and ASDAS ≥1.3 to <2.1). ASDAS: Axial Spondyloarthritis Disease Activity Score; HD: high disease: ID: inactive disease; LD: low disease; LDA: low disease activity; MI: multiple imputation; vHD: very high disease.
非 KM Figure
Figure 3Figure 3. Absolute MRI inflammation scores and remission rates to week 104 (OC). Only study participants enrolled in the SIJ and spine MRI sub-study are included in this analysis. MRI remission is defined as having an MRI SPARCC SIJ score < 2 or MRI Berlin spine score ≤2. The dashed vertical line between weeks 48 and 56 indicates entry into the combined open-label treatment period (BE MOVING) following week 52 of BE MOBILE 1 or BE MOBILE 2. a Only sub-study participants with baseline MRI SPARCC SIJ score ≥2 included. b Only sub-study participants with baseline MRI Berlin spine score >2 included. axSpA: axial spondyloarthritis; BKZ: bimekizumab: CfB: change from baseline; OC: observed case; MRI: magnetic resonance imaging; nr-axSpA: non-radiographic axSpA; PBO: placebo; Q4W: every 4 weeks; r-axSpA: radiographic axSpA; SD: standard deviation; SIJ: sacroiliac joint; SPARCC: Spondyloarthritis Research Consortium of Canada.
非 KM Figure